Specialised legal advice for life sciences & healthcare transactions
Transactions in the healthcare and pharmaceutical sectors are more than just traditional M&A projects. Regulatory frameworks, licensing issues, social security law considerations and compliance requirements have a significant impact on the structure, purchase price and integration potential of a deal. Anyone planning or reviewing a transaction in the healthcare or pharmaceutical sector requires specialist legal advisers with a deep understanding of the market and regulatory environment.
Taylor Wessing advises companies, investors and service providers on healthcare M&A and pharmaceutical M&A, both nationally and internationally. We combine M&A excellence with proven expertise in regulatory healthcare law, employment law and patent law, and support transactions throughout the entire investment cycle.
The Healthcare Industry – M&A in a Highly Regulated Environment
Hardly any other sector is as heavily regulated as healthcare. Transactions regularly involve:
- Hospital and statutory insurance physician law
- Medical device law and pharmaceutical regulation
- Licensing and approval procedures
- Cooperation with health insurance funds
- Procurement and state aid law
- Compliance in the healthcare sector
- Data protection in a medical context
Structure, financing and integration must take these regulatory realities into account. Our advice is therefore transaction-oriented and firmly based on regulatory expertise.
Analysis & guidance for decision-makers
M&A + Regulatory + IP/Patents: Interdisciplinary advice
The key added value lies in the integrated collaboration between our M&A teams and proven experts in regulatory healthcare law, social and administrative law, as well as IP and patent law. This interdisciplinary integration enables us to bring together transaction-related, regulatory and innovation-related issues at an early stage and manage them comprehensively.
This enables:
- robust due diligence reviews with in-depth regulatory analysis
- the secure structuring of authorisations and approvals
- early identification of social law risks
- the integration of regulatory requirements into purchase price and liability mechanisms
This results in solutions that are legally sound, regulatory-compliant and economically viable.
Mid-cap excellence in a highly regulated market
We have many years of experience in national and international healthcare transactions, particularly in the mid-cap segment. Our teams work efficiently, across disciplines and across locations.
With internationally integrated units in Europe, the US and Asia, we also support cross-border healthcare M&A and pharmaceutical industry M&A projects.
Let us have a conversation about your healthcare transaction.
Whether it is the sale of a hospital, a medical care centre platform, a pharmaceutical acquisition or a structurally complex deal – we can support you in navigating the legal and regulatory course for your transaction.
Contact usLatest news, insights & deals
Taylor Wessing at the IBA Annual Conference: Let’s Connect in Copenhagen
Taylor Wessing’s China Group wins three awards at the 2026 China Business Law Awards
Taylor Wessing advises the insolvency administrator on the sale of Sympatex Technologies GmbH to Pidigi
Taylor Wessing is advising Hypax on the acquisition of the Powerbox Group in a complex carve-out transaction from Cosel
